ChemInform Abstract: New Triterpenoids from the Fruiting Bodies of Ganoderma lucidum and Their Bioactivities.

Liu, Dong‐Ze; Zhu, Yi‐Qun; Li, Xiaofei; Shan, Wei‐Gang; Gao, Pengfei

doi:10.1002/chin.201452196

Cited by 3 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ethanolic and EtOAc extract compounds 12 β -acetoxy-3 β , 7 β -dihydroxy-11, 15, 23-trioxolanost-8-en-26-oic acid butyl ester ( 71 ) from fruiting bodies of G. lucidium showed significant inhibition against S. aureus and B. subtilis with MIC values of 68.5 µ M and 123.8 µ M, respectively (positive control ampicillin = 4.1 µ M and 19.3 µ M, resp.) (Liu et al 2014). …”

Section: Antibacterial Activities Of Compounds and Extracts Of Ganodementioning

confidence: 99%

Current and future perspective on antimicrobial and anti-parasitic activities of Ganoderma sp.: an update

Basnet

Liu

et al. 2017

Mycology

View full text Add to dashboard Cite

Medicinal mushroom Ganoderma sp. is considered to be a key source for the production of therapeutic agents. Our current review indicates that a limited number (<19%; 79 out of >430) of isolated compounds have been tested and known to be active against several microorganisms and parasites. In this review, we aim to summarise all the antimicrobial and anti-parasitic works on Ganoderma sp. displayed on web of science, google scholar and endnote X7 from 1932 to August 2016. We further present and discuss the structure of active compounds against microorganisms and parasites. In addition, we also discuss the possible further research to identify lead compounds from Ganoderma sp. as a novel strategy to combat the potential global emergence of bad bugs and parasites.

show abstract

Section: Antibacterial Activities Of Compounds and Extracts Of Ganodementioning

confidence: 99%

Current and future perspective on antimicrobial and anti-parasitic activities of Ganoderma sp.: an update

Basnet

Liu

et al. 2017

Mycology

View full text Add to dashboard Cite

show abstract

“…Since then, over 150 triterpenes were isolated including Ganoderic acid D, Ganoderic acid T, Ganoderic acid DM, and Ganodermanontirol [26]. Scientists have elucidated the orchestration of triterpenoid biological process in many publications [27]. Although the number of new triterpenoid identification is still growing, much attention has been focused on the pharmacological effects of medicinal fractions.…”

Section: The Active Ingredients In Ganoderma Lucidummentioning

confidence: 99%

Ganoderma lucidum on the inhibition of colorectal cancer

Ye¹,

Jenson²

2017

Hematol Med Oncol

View full text Add to dashboard Cite

Ganoderma lucidum is used in East Asian countries for treatment of a variety of diseases such as hypertension, cardiovascular disease, hepatopathy, chronic hepatitis and many cancers. Accumulating evidence has shown that Ganoderma lucidum has significant benefit for the prevention and treatment of different cancers, particularly colorectal cancer. This review summarizes current Ganoderma lucidum research on colorectal cancer in clinical patient studies, animal model for examination, and molecular mechanistic investigations.

show abstract

“…It is used as a healthy food and traditional medicine for treating insomnia, amnesia, fatigue and expectoration in Chinese folklore and has been included in the Pharmacopeia of the People's Republic of China (2015 Edition) (11). Previous phytochemical studies have elucidated that the major phytochemicals in G. lucidum are triterpenoids (12,13), though steroids, fatty acids, nucleotides, nucleobases, lactones and alkaloids have also been reported (14)(15)(16). Pharmacological investigations on G. lucidum have revealed that it possesses various bioactivities, including anti-inflammation (17), anti-diabetes (18), neuroprotecion (19), and anti-cancer (20) properties.…”

Section: Introductionmentioning

confidence: 99%

Triterpenoids from Ganoderma lucidum inhibit the activation of EBV antigens as telomerase inhibitors

Zheng

Chen

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Nasopharyngeal carcinoma (NPC) is a malignant disease that threatens the health of humans. To find effective agents for the inhibition of Epstein-Barr virus (EBV) infection, which is associated with NPC, a phytochemical investigation of Ganoderma lucidum was carried out in the present study. Five triterpenoids were identified, including ganoderic acid A (compound 1), ganoderic acid B (compound 2), ganoderol B (compound 3), ganodermanontriol (compound 4), and ganodermanondiol (compound 5), on the basis of spectroscopic analysis. An inhibition of EBV antigens activation assay was implemented to elucidate the triterpenoids from G. lucidum and potentially prevent NPC. All the triterpenoids showed significant inhibitory effects on both EBV EA and CA activation at 16 nmol. At 3.2 nmol, all the compounds moderately inhibited the activation of the two antigens. The activity of telomerase was inhibited by these triterpenoids at 10 µM. Molecular docking demonstrated that compound 1 was able to inhibit telomerase as a ligand. In addition, the physicochemical properties of these compounds were calculated to elucidate their drug-like properties. These results provided evidence for the application of these triterpenoids and whole G. lucidum in the treatment of NPC. IntroductionNasopharyngeal carcinoma (NPC) is a prevalent disease in southeastern Asia. In south China, it also threatens the health of humans; specifically, in the Cantonese region around Guangzhou, the incidence of NPC is 30-80 per 100,000 individuals annually (1). Radiotherapy and chemotherapy can improve the prognosis of patients with NPC, but the survival period remains low due to drug resistance and metastasis (2). Genetic predisposition, Epstein-Barr virus (EBV) infection, and environmental conditions are major factors that lead to malignant transformation (3). Though the detailed etiology of NPC remains unclear, it has been demonstrated that EBV infection has a pivotal role in the pathogenesis of NPC through EBV-encoded latent genes (4,5). Inhibiting EBV infection may represent a promising approach to preventing NPC (6).Telomerase is a pivotal holoenzyme involved in the repair of damaged telomeres, which is the protective end of eukaryotic chromosomes, through reverse transcription (7). Cells infected by EBV will lead to telomere dysfunction, and the telomere length was increased by the active telomerase (8). Increased telomerase activity also directly affects EBV infection by facilitating potential EBV gene expression early in virus inoculation (9). Telomerase inhibition is a possible therapeutic strategy for the treatment of cancer (10).Ganoderma lucidum (Leyss. ex Fr.) Karst is a mushroom distributed in the majority of areas in southern China. It is used as a healthy food and traditional medicine for treating insomnia, amnesia, fatigue and expectoration in Chinese folklore and has been included in the Pharmacopeia of the People's Republic of China (2015 Edition) (11). Previous phytochemical studies have elucidated that the major phytochemicals ...

show abstract

ChemInform Abstract: New Triterpenoids from the Fruiting Bodies of Ganoderma lucidum and Their Bioactivities.

Abstract: Two new triterpenoids (I) and (II) are isolated from the ethyl acetate extract of Ganoderma lucidum.

Cited by 3 publications

References 1 publication

Current and future perspective on antimicrobial and anti-parasitic activities of Ganoderma sp.: an update

Current and future perspective on antimicrobial and anti-parasitic activities of Ganoderma sp.: an update

Ganoderma lucidum on the inhibition of colorectal cancer

Triterpenoids from Ganoderma lucidum inhibit the activation of EBV antigens as telomerase inhibitors

Contact Info

Product

Resources

About